Autoimmune heparin-induced thrombocytopenia

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Autoimmune heparin-induced thrombocytopenia (aHIT) is characterized by anti-platelet factor 4 (PF4)-polyanion antibodies causing heparin-independent platelet activation.
• This condition can manifest in various clinical syndromes, including delayed-onset, persistent, and severe HIT with disseminated intravascular coagulation (DIC).

Purpose of the Study:

• To elucidate the mechanisms underlying aHIT, including the role of anti-PF4 antibodies and polyanions in platelet activation.
• To review current understanding of clinical manifestations and treatment strategies for aHIT.

Main Methods:

• Review of recent studies implicating anti-PF4 antibodies and platelet-associated polyanions in aHIT pathogenesis.
• Analysis of clinical data regarding treatment responses to various anticoagulants and immunotherapies.

Main Results:

• aHIT antibodies can bridge PF4 tetramers independently of heparin, facilitated by polyanions, leading to immune complex formation and platelet activation.
• Standard APTT-adjusted anticoagulants may be ineffective due to 'APTT confounding' in HIT-associated DIC.
• Non-APTT-adjusted anticoagulants (danaparoid, fondaparinux, DOACs) and high-dose IV immunoglobulin show promise for treatment and recovery.

Conclusions:

• aHIT involves complex immune mechanisms leading to significant thrombotic risk.
• Monitoring fibrin, D-dimer, and fibrinogen levels is crucial for assessing treatment response.
• Alternative anticoagulation strategies and IV immunoglobulin are recommended for managing aHIT, particularly persistent forms.